Researchers have now found a way to turn this emergency into a tool to protect the body from the devastating effects of another health emergency—a stroke.
In partnership with Gemini Untwined, XRlabs’ Surgical Intelligence platform generated custom implants in seconds and enabled successful craniopagus twin separation
Spiraling waves of neural activity appear and travel in the brain. Scientists hope to learn if these rotating waves on the move play a global role in sensing and interpreting internal and external stimuli, in laying down memory and in managing motor performance.
FiberSense has announced that its Continuous Glucose Monitoring (CGM) System has obtained CE marking under Regulation (EU) 2017/745 as a Class IIb medical device. The system is intended for continuous monitoring of blood sugar levels and glucose trends in adults with diabetes.
Researchers at the Federal University of São Paulo (UNIFESP) in Brazil have identified a molecule on the surface of cells that could be a promising therapeutic target against cancer.
A new study from RCSI University of Medicine and Health Sciences demonstrates a novel approach in anticancer vaccine development. The results, published in Molecular Therapy Oncology, present the first preclinical evidence showing the efficacy of an mRNA vaccine in targeting neuroblastoma, the deadliest childhood cancer.
Now, a study published in Science Translational Medicine offers a new strategy capable of identifying chemical compounds that could be further developed into antibiotic therapies with high selectivity for N. gonorrhoeae.
Researchers at the Technical University of Munich (TUM) have developed a lab-on-a-chip system called CellTrap. It makes it possible to observe the interactions between immune cells and cancer cells at the single-cell level.
AngioDynamics (Nasdaq:ANGO) announced today that it received FDA investigational device exemption (IDE) to initiate the RELIEF study.
Researchers at the Medical University of Vienna have described a mechanism in metastatic colorectal cancer that has received little attention to date: A key target of existing therapies, the so-called epidermal growth factor receptor (EGFR), is likely to affect more than just the cancer cells themselves. The study shows that EGFR also influences certain immune cells in the tumor microenvironment—and thereby helps determine how effectively the body’s own defenses can combat the tumor.